Meta-analysis: The effects of gut flora modulation using prebiotics, probiotics and synbiotics on minimal hepatic encephalopathy

Alimentary Pharmacology and Therapeutics

Volumn 33, Issue 6, 2011, Pages 662-671

  Shukla, S ^a   Shukla, A ^a   Mehboob, S ^a,b   Guha, S ^c  

^a UNIVERSITY AT BUFFALO   (United States)

^b VA WESTERN NEW YORK HEALTHCARE SYSTEM   (United States)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GLUCAN; CYANOCOBALAMIN; INULIN; LACTULOSE; PECTIN; PLACEBO; PREBIOTIC AGENT; PROBIOTIC AGENT; PYRIDOXINE; RIBOFLAVIN; STARCH; SYNBIOTIC AGENT; THIAMINE;

ABDOMINAL PAIN; ABSENCE OF SIDE EFFECTS; ADULT; AGED; ANOREXIA; ARTICLE; BIFIDOBACTERIUM; BIFIDOBACTERIUM LONGUM; CINAHL; COCHRANE LIBRARY; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; EMBASE; FEMALE; GLUCOSURIA; HEPATIC ENCEPHALOPATHY; HUMAN; INTESTINE FLORA; LACTOBACILLUS; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS BULGARICUS; LACTOBACILLUS CASEI; LACTOBACILLUS PARACASEI; LACTOBACILLUS PLANTARUM; LEUCONOSTOC MESENTEROIDES; MAJOR CLINICAL STUDY; MALE; MEDLINE; META ANALYSIS; MINIMAL HEPATIC ENCEPHALOPATHY; PEDIACOCCUS PENTOSECEUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; STREPTOCOCCUS THERMOPHILUS; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VOMITING;

ADULT; AGED; DIETARY SUPPLEMENTS; FEMALE; HEPATIC ENCEPHALOPATHY; HUMANS; INTESTINES; MALE; MIDDLE AGED; PREBIOTICS; PROBIOTICS; SYNBIOTICS;

EID: 79951678831     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2010.04574.x     Document Type: Article

References (46)

1. Rikkers L, Jenko P, Rudman D, Freides D,. Subclinical hepatic encephalopathy: detection, prevalence, and relationship to nitrogen metabolism. Gastroenterology 1978; 75: 462-9. (Pubitemid 9003354)
2. Wein C, Koch H, Popp B, Oehler G, Schauder P,. Minimal hepatic encephalopathy impairs fitness to drive. Hepatology 2004; 39: 739-45. (Pubitemid 38337653)
3. Bajaj JS, Saeian K, Schubert CM, et al. Minimal hepatic encephalopathy is associated with motor vehicle crashes: the reality beyond the driving test. Hepatology 2009; 50: 1175-83.
4. Dhiman RK, Chawla YK,. Minimal hepatic encephalopathy: time to recognise and treat. Trop Gastroenterol 2008; 29: 6-12.
5. Amodio P,. Health related quality of life and minimal hepatic encephalopathy. It is time to insert quality in health care. J Gastroenterol Hepatol 2009; 24: 329-30.
6. Bajaj JS,. Minimal hepatic encephalopathy matters in daily life. World J Gastroenterol 2008; 14: 3609-15.
7. Bajaj JS, Hafeezullah M, Zadvornova Y, et al. The effect of fatigue on driving skills in patients with hepatic encephalopathy. Am J Gastroenterol 2009; 104: 898-905.
8. Groeneweg M, Quero JC, De Bruijn I, et al. Subclinical hepatic encephalopathy impairs daily functioning. Hepatology 1998; 28: 45-9. (Pubitemid 28299984)
9. Schomerus H, Hamster W,. Quality of life in cirrhotics with minimal hepatic encephalopathy. Metab Brain Dis 2001; 16: 37-41. (Pubitemid 33064035)
10. Gibson GR, Roberfroid MB,. Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics. J Nutr 1995; 125: 1401-12.
11. Fuller R,. Probiotics in man and animals. J Appl Bacteriol 1989; 66: 365-78.
12. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF,. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses. Lancet 1999; 354: 1896-900.
13. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 1-12. (Pubitemid 26120810)
14. Deeks JJ, Higgins J, Altman DG,. Analyzing data and undertaking meta-analyses. In:, Higgins J, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions 5.0.1. Oxford, UK: The Cochrane Collaboration, 2008; (chap 9): p. 278.
15. Liu Q, Duan ZP, Ha DK, Bengmark S, Kurtovic J, Riordan SM,. Synbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis. Hepatology 2004; 39: 1441-9. (Pubitemid 38569067)
16. Malaguarnera M, Greco F, Barone G, Gargante MP, Toscano MA,. Bifidobacterium longum with fructo-oligosaccharide (FOS) treatment in minimal hepatic encephalopathy: a randomized, double-blind, placebo-controlled study. Dig Dis Sci 2007; 52: 3259-65. (Pubitemid 47512537)
17. Bajaj JS, Saeian K, Christensen KM, et al. Probiotic yogurt for the treatment of minimal hepatic encephalopathy. Am J Gastroenterol 2008; 103: 1707-15.
18. Lata J, Jurankova J, Pribramska V, et al. Effect of administration of Escherichia coli Nissle (Mutaflor) on intestinal colonisation, endo-toxemia, liver function and minimal hepatic encephalopathy in patients with liver cirrhosis. Vnitr Lek 2006; 52: 215-9.
19. Horsmans Y, Solbreux PM, Daenens C, Desager JP, Geubel AP,. Lactulose improves psychometric testing in cirrhotic patients with subclinical encephalopathy. Aliment Pharmacol Ther 1997; 11: 165-70. (Pubitemid 27067349)
20. Watanabe A, Sakai T, Sato S, et al. Clinical efficacy of lactulose in cirrhotic patients with and without subclinical hepatic encephalopathy. Hepatology 1997; 26: 1410-4. (Pubitemid 27520004)
21. Prasad S, Dhiman RK, Duseja A, Chawla YK, Sharma A, Agarwal R,. Lactulose improves cognitive functions and health-related quality of life in patients with cirrhosis who have minimal hepatic encephalopathy. Hepatology 2007; 45: 549-59. (Pubitemid 46450607)
22. Dhiman RK, Sawhney MS, Chawla YK, Das G, Ram S, Dilawari JB,. Efficacy of lactulose in cirrhotic patients with subclinical hepatic encephalopathy. Dig Dis Sci 2000; 45: 1549-52.
23. Zeng Z, Li YY,. Effects of lactulose treatment on the course of subclinical hepatic encephalopathy. Zhonghua Yi Xue Za Zhi 2003; 83: 1126-9.
24. Mas A, Rodes J, Sunyer L, et al. Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial. J Hepatol 2003; 38: 51-8. (Pubitemid 36078524)
25. Loguercio C, Federico A, De Girolamo V, Ferrieri A, Del Vecchio Blanco C,. Cyclic treatment of chronic hepatic encephalopathy with rifaximin. Results of a double-blind clinical study. Minerva Gastroenterol Dietol 2003; 49: 53-62. (Pubitemid 36505760)
26. Salerno F, Moser P, Maggi A, Vitaliani G, Benetti G,. Effects of long-term administration of low-dose lactitol in patients with cirrhosis but without overt encephalopathy. J Hepatol 1994; 21: 1092-6.
27. Heredia D, Teres J, Orteu N, Rodes J,. Lactitol vs. lactulose in the treatment of chronic recurrent portal-systemic encephalopathy. J Hepatol 1988; 7: 106-10.
28. Morgan MY, Hawley KE, Stambuk D,. Lactitol versus lactulose in the treatment of chronic hepatic encephalopathy. A double-blind, randomised, cross-over study. J Hepatol 1987; 4: 236-44. (Pubitemid 17044986)
29. Riggio O, Balducci G, Ariosto F, et al. Lactitol in the treatment of chronic hepatic encephalopathy-a randomized cross-over comparison with lactulose. Hepatogastroenterology 1990; 37: 524-7.
30. Pai CH, Huang YS, Jeng WC, Chan CY, Lee SD,. Treatment of porto-systemic encephalopathy with lactitol verus lactulose: a randomized controlled study. Zhonghua Yi Xue Za Zhi (Taipei) 1995; 55: 31-6.
31. Morgan MY, Alonso M, Stanger LC,. Lactitol and lactulose for the treatment of subclinical hepatic encephalopathy in cirrhotic patients. A randomised, cross-over study. J Hepatol 1989; 8: 208-17. (Pubitemid 19074358)
32. McClain CJ, Potter TJ, Kromhout JP, Zieve L,. The effect of lactulose on psychomotor performance tests in alcoholic cirrhotics without overt hepatic encephalopathy. J Clin Gastroenterol 1984; 6: 325-9. (Pubitemid 14053702)
33. Sharma BC, Sharma P, Agrawal A, Sarin SK,. Secondary prophylaxis of hepatic encephalopathy: an open-label randomized controlled trial of lactulose versus placebo. Gastroenterology 2009; 137: 885-91, e1.
34. Malaguarnera M, Gargante MP, Malaguarnera G, et al. Bifidobacterium combined with fructo-oligosaccharide versus lactulose in the treatment of patients with hepatic encephalopathy. Eur J Gastroenterol Hepatol 2010; 22: 199-206.
35. Sharma P, Sharma BC, Sarin SK,. Predictors of nonresponse to lactulose for minimal hepatic encephalopathy in patients with cirrhosis. Liver Int 2009; 29: 1365-71.
36. Gentile S, Guarino G, Romano M, et al. A randomized controlled trial of acarbose in hepatic encephalopathy. Clin Gastroenterol Hepatol 2005; 3: 184-91. (Pubitemid 40220314)
37. Romero-Gomez M, Boza F, Garcia-Valdecasas MS, Garcia E, Aguilar-Reina J,. Subclinical hepatic encephalopathy predicts the development of overt hepatic encephalopathy. Am J Gastroenterol 2001; 96: 2718-23.
38. Das A, Dhiman RK, Saraswat VA, Verma M, Naik SR,. Prevalence and natural history of subclinical hepatic encephalopathy in cirrhosis. J Gastroenterol Hepatol 2001; 16: 531-5. (Pubitemid 34188860)
39. Riordan SM, Williams R,. Gut flora and hepatic encephalopathy in patients with cirrhosis. N Engl J Med 2010; 362: 1140-2.
40. Riordan SM, Skinner NA, McIver CJ, et al. Synbiotic-associated improvement in liver function in cirrhotic patients: relation to changes in circulating cytokine messenger RNA and protein levels. Microbial Ecology in Health and Disease 2007; 19: 7-16. (Pubitemid 46569379)
41. Heilpern D, Szilagyi A,. Manipulation of intestinal microbial flora for therapeutic benefit in inflammatory bowel diseases: review of clinical trials of probiotics, pre-biotics and synbiotics. Rev Recent Clin Trials 2008; 3: 167-84.
42. Hoveyda N, Heneghan C, Mahtani KR, Perera R, Roberts N, Glasziou P,. A systematic review and meta-analysis: probiotics in the treatment of irritable bowel syndrome. BMC Gastroenterol 2009; 9: 15.
43. McFarland LV, Dublin S,. Meta-analysis of probiotics for the treatment of irritable bowel syndrome. World J Gastroenterol 2008; 14: 2650-61.
44. DSouza AL, Rajkumar C, Cooke J, Bulpitt CJ,. Probiotics in prevention of antibiotic associated diarrhoea: meta-analysis. BMJ 2002; 324: 1361.
45. Elia M, Engfer MB, Green CJ, Silk DB,. Systematic review and meta-analysis: the clinical and physiological effects of fibre-containing enteral formulae. Aliment Pharmacol Ther 2008; 27: 120-45. (Pubitemid 350256602)
46. Randolph C, Hilsabeck R, Kato A, et al. Neuropsychological assessment of hepatic encephalopathy: ISHEN practice guidelines. Liver Int 2009; 29: 629-35.